Evaluation: New Symptomatic Approaches for the Treatment of Alzheimer's Disease
*
*
*
Use the scale: 1=Poor, 2=Fair, 3=Good, 4=Very Good, 5=Excellent
12345
Identify therapeutic approaches to cognitive, functional, and behavioral symptoms of AD
Identify symptomatic treatments for AD in late-stage development
Analyze new models of assessing symptomatic treatment responses
*
Please use the scale: 1=Not at all familiar, 2=Somewhat familiar, 3=Familiar, 4=Very familiar, 5=Expert on this subject, 6=N/A for me
123456
The role in the progression of AD of synaptic changes that occur as the result of amyloid and tau effects
The Goal Attainment Scale (GAS) rationale and the applicability of this scale to measure the efficacy of an intervention in the management of patients with AD
The 5-HT6 antagonists and the alpha-7 nicotinic partial agonists and the rationale behind their potential value in the symptomatic treatment of mild and moderate AD
That when administered as adjunctive treatment to donepezil in patients with moderate AD, phase II data suggest that the 5-HT6 receptor antagonist idalopirdine may significantly improve anxiety
The alpha-7 nicotinic partial agonist enceniecline may be associated with mild gastrointestinal effects, mainly nausea and constipation, which occurred in approximately 10% of treated patients
Idalopirdine may be associated with generally mild and transient increases in levels of alanine amino-transferase and gamma-glutamyl transferase
*
Please use the scale: 1=Not at all familiar, 2=Somewhat familiar, 3=Familiar, 4=Very familiar, 5=Expert on this subject, 6=N/A for me
123456
The role in the progression of AD of synaptic changes that occur as the result of amyloid and tau effects
The Goal Attainment Scale (GAS) rationale and the applicability of this scale to measure the efficacy of an intervention in the management of patients with AD
The 5-HT6 antagonists and the alpha-7 nicotinic partial agonists and the rationale behind their potential value in the symptomatic treatment of mild and moderate AD
That when administered as adjunctive treatment to donepezil in patients with moderate AD, phase II data suggest that the 5-HT6 receptor antagonist idalopirdine may significantly improve anxiety
The alpha-7 nicotinic partial agonist enceniecline may be associated with mild gastrointestinal effects, mainly nausea and constipation, which occurred in approximately 10% of treated patients
Idalopirdine may be associated with generally mild and transient increases in levels of alanine amino-transferase and gamma-glutamyl transferase
*
Please use the scale: 1=Never, 2=Not Often, 3=Sometimes, 4=Often, 5=Always, 6=N/A
123456
Assess symptoms using an individualized measure such as the Goal Attainment Scale
Stay up-to-date on emerging evidence for symptomatic treatments, such as idalopirdine and encenicline
Consider the systems impact when choosing a treatment regimen for patients with Alzheimer’s
*
Please use the scale: 1=Never, 2=Not Often, 3=Sometimes, 4=Often, 5=Always, 6=N/A
123456
Assess symptoms using an individualized measure such as the Goal Attainment Scale
Stay up-to-date on emerging evidence for symptomatic treatments, such as idalopirdine and encenicline
Consider the systems impact when choosing a treatment regimen for patients with Alzheimer’s
*
Use the scale: 1=Strongly Disagree, 2=Disagree, 3=Neutral, 4=Agree, 5=Strongly Agree
12345
Overall, the activity met my learning needs
The information presented was without promotional or commercial bias
The information presented was scientifically rigorous and evidence based
The information presented provided appropriate and effective opportunities for active learning (discussion, Q&A)
The information presented promoted improvements or quality in health care
The quality of the educational process was satisfactory and appropriate
The information provided with regard to faculty relations met my needs for disclosure
The speakers were knowledgeable and presented the information clearly
The format of the discussion was relevant and enhanced my knowledge of the subject
The registration process for this meeting was efficient and professional
*
Use the scale: 1=Poor, 2=Fair, 3=Good, 4=Very Good, 5=Excellent
12345
Jeffrey L. Cummings, MD, ScD (Program Chair)
Alireza Atri, MD, PhD
Kenneth Rockwood, MD, FRCPC, FRCP
*
*
*
*